Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy
- PMID: 17875751
- DOI: 10.1158/1078-0432.CCR-07-0182
Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy
Abstract
Cancer immunotherapy has focused on inducing and expanding CTLs and improving the immune recognition of weak antigenic determinants expressed by tumors. However, few positive clinical outcomes have been reported due, in part, to tumor-associated immunologic tolerance, supporting the need for an emphasis on overcoming immunosuppression. Systemic immunosuppression is associated with abnormal myelopoiesis secondary to tumor growth, myelosuppressive therapy, and growth factor administration and subsequent expansion/mobilization of bone marrow-derived immunosuppressive cells. These myeloid-derived suppressor cells (MDSC) reduce activated T-cell number and inhibit their function by multiple mechanisms, including depletion of l-arginine by arginase-1 (ARG1) production of nitric oxide, reactive oxygen species, and reactive nitrogen oxide species by inducible nitric oxide synthase. Increased numbers of MDSCs are associated with neoplastic, inflammatory, infectious, and graft-versus-host diseases where they restrain exuberant or novel T-cell responses. In this review, we discuss critical components of MDSC-mediated suppression of T-cell function, including cellular expansion and activation-induced secretion of immunosuppressive mediators. Both components of MDSC bioactivity are amenable to pharmacologic intervention as discussed herein. We also focus on the relationship between MDSCs, tumor growth, therapeutic responses, and the mechanisms of cellular expansion, activation, and immunosuppression.
Similar articles
-
Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.Int Immunopharmacol. 2009 Jul;9(7-8):937-48. doi: 10.1016/j.intimp.2009.03.021. Epub 2009 Apr 9. Int Immunopharmacol. 2009. PMID: 19362167
-
Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.J Immunol. 2009 Feb 15;182(4):1818-28. doi: 10.4049/jimmunol.0802430. J Immunol. 2009. PMID: 19201833
-
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.Immunol Rev. 2008 Apr;222:162-79. doi: 10.1111/j.1600-065X.2008.00602.x. Immunol Rev. 2008. PMID: 18364001 Review.
-
Antigen specificity of immune suppression by myeloid-derived suppressor cells.J Leukoc Biol. 2011 Jul;90(1):31-6. doi: 10.1189/jlb.0111021. Epub 2011 Apr 12. J Leukoc Biol. 2011. PMID: 21486906 Review.
-
Myeloid cell population dynamics in healthy and tumor-bearing mice.Int Immunopharmacol. 2011 Jul;11(7):783-8. doi: 10.1016/j.intimp.2011.03.003. Epub 2011 Mar 22. Int Immunopharmacol. 2011. PMID: 21406269 Review.
Cited by
-
Concomitant active tuberculosis prolongs survival in non-small cell lung cancer: a study in a tuberculosis-endemic country.PLoS One. 2012;7(3):e33226. doi: 10.1371/journal.pone.0033226. Epub 2012 Mar 16. PLoS One. 2012. PMID: 22438899 Free PMC article.
-
Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility.PLoS One. 2011 Feb 10;6(2):e17014. doi: 10.1371/journal.pone.0017014. PLoS One. 2011. PMID: 21347333 Free PMC article.
-
Rapid Profiling of Tumor-Immune Interaction Using Acoustically Assembled Patient-Derived Cell Clusters.Adv Sci (Weinh). 2022 Aug;9(22):e2201478. doi: 10.1002/advs.202201478. Epub 2022 May 25. Adv Sci (Weinh). 2022. PMID: 35611994 Free PMC article.
-
Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation.J Invest Dermatol. 2009 Oct;129(10):2451-62. doi: 10.1038/jid.2009.96. Epub 2009 Apr 23. J Invest Dermatol. 2009. PMID: 19387481 Free PMC article.
-
Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.J Mol Med (Berl). 2009 Jun;87(6):595-612. doi: 10.1007/s00109-009-0455-2. Epub 2009 Mar 7. J Mol Med (Berl). 2009. PMID: 19271159 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous